.. Bayer’s regorafenib showed 50 percent stabilization price in RCC patients Bayer today announced outcomes from a Stage II trial of regorafenib , a potent oral multi-kinase inhibitor, which demonstrated that treatment with regorafenib led to a 31 % partial response rate and 50 % stabilization price in individuals with metastatic renal cell carcinoma . These data were presented within an oral program at the joint 15th Congress of the European Cancers Organisation and 34th Congress of the European Culture for Medical Oncology . Preliminary results out of this research were presented previously this season at the 45th American Culture of Clinical Oncology Annual Congress, Might 29 – Jun 2, 2009, Orlando, Florida.The CMA that includes 35,000 doctors provides adopted an official policy that recommends the regulation and legalization of cannabis. Friday in Anaheim California Medical Association adopted the new stance at its annual meeting. The board of trustees of the CMA, the biggest physician group in California, followed the plan at its interacting with in Sacramento unanimously, according to a statement on the CMA website. California is among 16 says where medical marijuana is definitely legal, making it possible for doctors to recommend the drug to their patients.